Keyphrases
Clinical Trials
100%
Neurofibromatosis Type I
100%
Cutaneous Neurofibroma
100%
Neurofibromatosis Type 1 (NF-1)
100%
Core Outcome Domains
100%
Journal Editors
33%
Systematic Literature Review
33%
Healthcare Professionals
33%
Patient Relatives
33%
Drug Regulatory Agencies
33%
Outcome Domains
33%
Medical Representative
33%
E-Delphi
33%
Steering Committee
16%
Clinical Assessment
16%
Pharmaceutical Companies
16%
International Workshop
16%
Participation Rate
16%
Committee Member
16%
Patient Perception
16%
High Burden
16%
Patient Satisfaction
16%
Medical Treatment
16%
Health Perception
16%
Study within a Trial
16%
Delphi Method
16%
Phase Lead
16%
International Patients
16%
All Clinical Trials
16%
Outcome Measurement Instruments
16%
Impact on Daily Life
16%
Pharmaceutical Representatives
16%
Delphi Consensus
16%
E-survey
16%
Validated Approach
16%
Medicine and Dentistry
Clinical Trial
100%
Neurofibromatosis Type I
100%
Plexiform Neurofibroma
100%
Systematic Review
33%
Combination Therapy
16%
Outcome Assessment
16%
Clinical Assessment
16%
Patient Satisfaction
16%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Neurofibromatosis Type 1
100%
Neurofibroma
100%
Combination Therapy
16%
Neuroscience
Neurofibroma
100%
Neurofibromatosis Type 1
100%
Clinical Assessment
16%
Biochemistry, Genetics and Molecular Biology
Clinical Trial
100%
Patient Satisfaction
50%